Vornorexant（Cat No.:I044386）is a dual orexin receptor antagonist (DORA) that selectively blocks orexin-1 and orexin-2 receptors, which regulate wakefulness and arousal. By inhibiting these receptors, Vornorexant promotes sleep onset and maintenance without the dependency risks associated with traditional sedative-hypnotics. It exhibits a favorable pharmacokinetic profile, including sustained receptor occupancy and minimal next-day residual effects. Vornorexant is under investigation for the treatment of insomnia and other sleep-related disorders. Its targeted mechanism supports natural sleep architecture, making it a promising candidate for safer, more effective sleep therapy options.